Sexual repercussions of cancer and its treatments have long been considered of minor importance. However, the sexual dimension of cancer patients has recently been given particular consideration, resulting in an increased scientific interest and the development of international guidelines. In this paper, we detail the main sexual disorders encountered by both male and female cancer patients. Women are mostly affected by dyspareunia and decreased libido, while erectile dysfunction and decreased libido are predominant in men. These disorders may have a major impact on the couple’s life. We also describe the sexual adverse effects induced by the different cancer treatments and provide some advices and nonpharmacological treatments to manage them.
Working with the couple is of real interest in many medical situations, and particularly in the field of sexology. This article highlights the benefits of working with the couple, proposes different communication strategies, and comes to the conclusion that working in the relational system of patients is part of medical practice.
Nathalie Michaux(1), Maria-Laura Marotta(2), Marcelo Di Gregorio(3), Christine Reynaert(4)Published in the journal : September 2018Category : Congrès de médecine sexuelle
This article explains in a very concrete way how to approach sexuality with a female patient during a consultation, irrespective of the medical specialty.
Marcelo Di Gregorio MD1, Francis Lorge MD(1), Christine Reynaert MD(2), Nathalie Michaux MD(3)Published in the journal : September 2018Category : Congrès de médecine sexuelle
a sexological consultation is a delicate task that requires a specific approach. The first difficulty in managing a sexual problem is to get the issue on the table. Patients visit their physician because of problems concerning sexuality/ sexual activity and their consequences. The question is whether general practitioners prefer to avoid answering these questions or if they are willing to respond actively. If so, to what extent are they able to answer the patient’s question? And would they agree to attend specific training courses and to work in collaboration with specialists within a network system. This work’s aim was to provide tools for acquiring and mastering specific medical knowledge and practical skills regarding male sexual disorders (erectile dysfunction, ejaculation and libido disorders) and to facilitate the acquisition of communication skills for the consultation (doctor / patient relationship).
Olivier S. DescampsPublished in the journal : September 2018Category : GRAPA
The "sneaky" aspect of the risk associated with high blood cholesterol given its asymptomatic nature before complications arise makes hypolipidemic treatment often problematic for our patients. This is especially so because the side effects that can occur such as myalgia and the polemics diffused through the media by some critics cause worry and doubts in our patients. In this article, we will discuss three of the most frequently encountered problems and how to address them.
Guselkumab is a selective interleukin-23 inhibitor that has been marketed and reimbursed since a few months in Belgium. We conducted a literature review in order to assess the efficacy and safety of guselkumab.
The news from the GRAPA provide a summary of the presentations made at the 9th GRAPA symposium, with a focus on treatment adherence in the prevention of cardiovascular diseases, mainly in the areas of lipidology, diabetology, and rhythmology. The presentations also addressed related topics, such as therapeutic inertia, therapeutic education, empowerment, and the impact of treatment-related adverse events and media controversies on the initiation and continuation of cardiovascular medications. Finally, arguments for the control of cardiovascular risk factors in the prevention of atrial fibrillation, based on recent medical literature, are also presented.
After thousands of hemophilic patients were infected with HIV and HCV, and thanks to major advances in biotechnology, recombinant factor VIII has emerged as a first-line or reference treatment for most factor VIII-deficient patients (hemophilia A). The development of neutralizing antibodies (inhibitors) is currently the most severe and feared complication in hemophilia A replacement therapy. The respective immunogenicity of plasma and recombinant factor VIII concentrates has been debated for many years, with multiple studies providing contradictory results.
Xultophy® is a new combination product consisting of basal insulin (degludec) and a GLP-1 agonist (liraglutide). In this article, we analyzed recent literature in order to find out its potential advantages in general and compared to basal insulin in particular, as well as to clarify its role in the therapeutic management of insulinrequiring type 2 diabetes.
Kevin Ackenine(1), Samuele Iesari1, (2), Maxime Foguenne(1), Chantal De Reyck(1), Eliano Bonaccorsi Riani(1), Olga Ciccarelli(1), Laurent Coubeau(1), Quirino Lai(3), Mina Komuta(4), Pierre Gianello(5), Jan Lerut(1)Published in the journal : July 2018Category : Mémoires de Recherche Clinique
The efficacy of anti-lymphocyte serum (ALS) induction remains inconclusive in liver transplantation (LT) due to poorly designed trials.